Related Experiment Video
Updated: Jan 30, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells
Xiaoxuan Li1, Zhiwei Zou2, Jiao Tang1
1Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, P.R. China.
Abstract:
Nitric oxide synthase 1 (NOS1) has been reported to promote various cancer processes including chemoresistance. However, the role of NOS1 in chemoresistance has remained unclear. ATP-binding cassette, subfamily G, member 2 (ABCG2) has been identified as a molecular cause of multidrug resistance in a number of cancer types, including ovarian cancer. The present study observed that in ovarian cancer cells, the expression of ABCG2 was significantly upregulated in response to cis-diamminedichloroplatinum (cisplatin/DDP) treatment, in addition the expression of NOS1 exhibited an increasing trend. Additionally, the levels of NOS1 and ABCG2 in chemoresistant ovarian cancer profiles in Gene Expression Omnibus datasets (GSE26712 and GSE51373) were higher than in chemosensitive profiles. Furthermore, overexpression of NOS1 could upregulate ABCG2 expression, and expression of ABCG2 was inhibited by NOS1 selective inhibitor (N-PLA). In assays of cell survival, NOS1 appeared to increase the potential for DDP resistance, and this effect was reversed by addition of ABCG2 inhibitor (verapamil). The present study indicated that NOS1-induced chemoresistance was partly mediated by the upregulation of ABCG2 expression. This result suggests a link between the expression of NOS1 and the ABCG2-associated chemoresistance in ovarian cancer.
Insights
Nitric oxide synthase 1 (NOS1) promotes ovarian cancer chemoresistance by upregulating ABCG2. Inhibiting NOS1 or ABCG2 can reverse this resistance, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Nitric oxide synthase 1 (NOS1) is implicated in cancer progression and chemoresistance.
- ATP-binding cassette, subfamily G, member 2 (ABCG2) is a known driver of multidrug resistance, particularly in ovarian cancer.
Purpose of the Study:
- To investigate the role of NOS1 in chemoresistance in ovarian cancer.
- To determine the relationship between NOS1 and ABCG2 expression in cisplatin-resistant ovarian cancer.
Main Methods:
- Ovarian cancer cells were treated with cisplatin (DDP).
- Expression levels of NOS1 and ABCG2 were analyzed using cell culture and Gene Expression Omnibus datasets (GSE26712, GSE51373).
- Functional assays involved NOS1 overexpression, NOS1 inhibition (N-PLA), and ABCG2 inhibition (verapamil).
Main Results:
- Cisplatin treatment upregulated both NOS1 and ABCG2 expression in ovarian cancer cells.
- Higher NOS1 and ABCG2 levels were observed in chemoresistant ovarian cancer profiles.
- NOS1 overexpression increased ABCG2 expression, while NOS1 inhibition decreased it.
- NOS1 enhanced DDP resistance, an effect reversed by ABCG2 inhibition.
Conclusions:
- NOS1 contributes to chemoresistance in ovarian cancer, partly through the upregulation of ABCG2.
- The NOS1-ABCG2 pathway represents a potential therapeutic target for overcoming chemoresistance in ovarian cancer.
Related Concept Videos
Cell Specific Gene Expression
Cell Specific Gene Expression
Binet's Contribution to Measures of Intelligence
Wechsler's Contribution to Measures of Intelligence
Ovarian Cycle
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...

